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Background/Aims: Many patients with acute paraquat (PQ) intoxication die even at low PQ concentrations,
whereas others with similar concentrations recover. Therefore, it is possible that individual differences in
antioxidant capacity are responsible for the variable clinical outcome in patients with acute PQ intoxication.  
Methods: We investigated whether there was a relationship between the genetic polymorphisms of SOD (V16A),
catalase (C262T), and GPX1 (C593T) in 62 patients with acute PQ intoxication and the clinical outcomes of these
patients.  
Results: The frequency of the Mn-SOD V/V, V/A, and A/A genotypes were 56.3, 43.5, and 0% in survivors and
86.9, 13.1, and 0% in non-survivors (p > 0.05). The GPX1 C/C, C/T, and T/T genotypes were present in 100, 0,
and 0% of all subjects. The catalase C/C, C/T, and T/T genotypes were present in 100, 0, and 0% of survivors,
and in 82.6, 17.4, and 0% of non-survivors. Neither erythrocyte SOD activity nor catalase activity were
significantly different between survivors and non-survivors. 
Conclusions: No association was found between clinical outcome of acute PQ intoxication and the genetic
polymorphism of GPX1 (C593T) or the genetic polymorphisms or enzyme activity of superoxide dismutase
(V16A) or catalase (C262T). (Korean J Intern Med 2010;25:422-428)
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INTRODUCTION
Paraquat (PQ) catalyzes the formation of reactive oxygen
species (ROS). Within aerobically living cells, ROS are
continuously produced to carry out biological reactions
[1]. Overproduction, however, can damage cell membranes
through the peroxidation of membrane polyunsaturated
fatty acids. Ingestion of PQ results in subsequent redox
cycling and the generation of ROS that can trigger lung
injury due to preferential uptake and accumulation of
PQ in the lungs [2]. PQ intoxication thus frequently causes
death due to respiratory failure [3,4].
Plasma PQ concentration is an excellent prognostic
indicator of patient outcome [5,6]. Nevertheless, many
patients succumb to PQ at low concentrations, whereas
others with similar PQ concentrations recover [7]. The
activity of ROS is countered by intracellular antioxidant
defenses provided by superoxide dismutase (SOD), catalase,
and glutathione peroxidase/reductase [8]. Individual
differences in antioxidant capacity could account for
variable clinical outcomes. To date, however, there are no
reported associations between total antioxidant levels in
the serum and the clinical outcome of patients with acute
PQ intoxication [9]. 
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The relative importance of individual antioxidant
capacity depends on the nature of the oxidant in question
and the target molecule that must be protected from
oxidative damage. Considering that ROS are formed
mainly in cells that possess strong antioxidant enzymes,
individual differences in the activity of these enzymes
might be responsible for variable clinical outcome despite
similar plasma PQ levels [10]. We investigated whether
there was an association between clinical outcome and
genetic polymorphisms of SOD (V16A) [11], catalase
(C262T) [12], and glutathione peroxidase 1 (GPX1)
(C593T) [13] as well as antioxidant enzyme activity in
patients with acute PQ intoxication. 
METHODS
Patient characteristics
This study was approved by the Soonchunhyang
Cheonan Hospital’s Institutional Review Board and all
procedures were performed after receiving informed
consent. In 2008, we reported an association between
plasma PQ levels and clinical outcome in 375 patients with
acute PQ intoxication during 2006 and 2007 [8]. The
upper limit of PQ levels among survivors was 3.44 g/mL
at 2 hours, 2.64 g/mL at 3 hours, 1.75 g/mL at 4 hours,
1.31 g/mL at 5 hours, 1.2 g/mL at 8 hours, and 0.16 g/mL
at 24 hours, whereas the lower limit among non-survivors
was 0.92 g/mL at 2 hours, 0.54 g/mL at 4 hours, 0.12
g/mL at 5 hours, 0.02 g/mL at 12 hours, and 0.01 g/mL at
24 hours (Fig. 1A). These levels can be divided into a dead
zone (above the upper line), gray zone (between the two
lines), and a safe zone (below the low line; Fig. 1B). In the
gray zone, some patients succumb while others with
similar PQ levels recover. In 2008, 62 out of 320 cases
with acute PQ intoxication could be categorized into the
gray zone, retrospectively. In this study, we evaluated
genetic polymorphisms in stored whole blood collected
from these patients and measured catalase and SOD
activity.
All patients attempted suicide by PQ ingestion and
were admitted to the Institute of Pesticide Poisoning,
Soonchunhyang University Cheonan Hospital, from
January through December 2008. The age, gender,
clinical characteristics, and baseline laboratory findings
are summarized in Table 1. Standard medical emergency
procedures were provided for all patients. Briefly, gastric
lavage was performed within 2 hours of PQ ingestion for
all patients that immediately presented to the emergency
room (ER). For those who had been intoxicated for up to
12 h before presenting to the ER, 100 g fuller’s earth in
200 mL 20% mannitol was given. Hemoperfusion was
Figure 1. (A) The upper and lower limit of paraquat level among survivors and non-survivors in 375 patients with acute paraquat
intoxication (x: non-survivors, o: survivors). (B) These levels can be divided into a dead zone (above the upper line), gray zone
(between the two lines; may die or may live), and a safe zone (below the lower line).
A B424 The Korean Journal of Internal Medicine Vol. 25, No. 4, December 2010
performed on patients that had a positive urinary PQ test
on arrival to the ER. The amount ingested was estimated
based on the number of swallows, where one mouthful was
considered 20 mL. High-resolution computer tomography
(HRCT) was performed 7 days after ingestion, and a
follow-up HRCT was performed 1 week later if any
abnormality was detected. Survivors were defined as those
patients who survived more than 3 months after PQ
ingestion, maintained stable vital signs, had no evidence
of progressive organ failure (especially the kidneys and
lungs), and had no specific complaints. 
Urinary PQ levels were measured semi-quantitatively
by a dithionite method, and the plasma PQ levels were
evaluated by HPLC. Malonyldialdehyde (MDA) was
measured with an assay kit (NWLSSTM, Northwest Life
Science Specialties LLC, Vancouver, Canada).
SOD assay
SOD activity in erythrocyte lysates was measured using
a commercially available assay kit (Cayman Chemical
Superoxide Dismutase Assay Kit, Ann Arbor, MI, USA).
This kit uses tetrazolium salt to detect superoxide radicals
generated by xanthine oxidase and hypoxanthine. One
unit of SOD is defined as the amount of enzyme needed to
exhibit 50% dismutation of a superoxide radical. This
assay measures all three types of SOD (Cu/Zn-, Mn-, and
Fe-SOD).
Catalase assay
Catalase activity in erythrocyte lysates was measured
using a commercially available assay kit (Cayman
Chemical Catalase Assay Kit). This kit uses the peroxidase
function of catalase to determine enzyme activity. The
method is based on the reaction of the enzyme with
methanol in the presence of an optimal concentration of
H2O2. 
Genotyping
Genotyping was performed based on previously
published reports [12-15]. Genomic DNA was extracted
from peripheral white cells using the commercially available
Chemagic DNA blood kit special (960 preparations from
Table 1. Baseline characteristics of patients
Characteristics Mean ± SD Min, Max (median)
Age, yr 47.5 ± 13.1 15, 70 (49)
Male/Female, n  32/30
Amount of PQ ingested, mL 36.3 ± 63.6 5.00, 500.00 (20)
Time elapsed after PQ ingestion, hr 7.30 ± 5.72 0.50, 24.00 (5)
PQ level, µg/mL 0.44 ± 0.53 0.01, 1.91 (0.22)  
TAS, mmol/L 1.71 ± 0.23 1.23, 2.42 (1.68)
MDA, µM 11.8 ± 4.0 4.0, 25.0 (11.0)
WBC, × 103/L 10.87 ± 5.98 4.10, 44.50
Hemoglobin, g/dL 13.7 ± 2.0 6.9, 17.0
Hematocrit, % 40.4 ± 5.0 24.0, 48.6
Albumin, g/dL 4.2 ± 0.5 2.0, 5.6
Bilirubin, mg/dL 1.0 ± 1.0 0.2, 7.1
AST, IU/L 37.2 ± 26.5 13.0, 132.0
ALT, IU/L 28.8 ± 36.6 2.0, 292.0
BUN, mg/dL 12.7 ± 4.8 4.0, 33.0
Creatinine, mg/dL 0.7 ± 0.4 0.3, 2.4
Uric acid, mg/dL 4.7 ± 1.7 1.6, 10.6
Amylase, IU/L 207.1 ± 209.6 36.0, 1393.0
Lipase (IU/L) 42.2 ± 57.3 12.0, 459.0
pH 7.4 ± 0.1 7.2, 7.6
PaO2, mmHg 88.4 ± 15.7 31.2, 130.4
PQ, paraquat; TAS, total antioxidant status; MDA, malondialdehyde; WBC, white blood cell count; AST, aspartate aminotransferase; ALT, alanine
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200 µL blood) according to the manufacturer’s instructions
(Chemagen, Baesweiler, Germany) and amplified using
the following primers: MnSOD 47T>C, 5'-ggctgtgctttctcgtcttc-
3' and 5'-ccatcgaggcactccttcta-3'; Catalase -262C>T,
5'-ccaggattgctgacttttt-3' and 5'-tgtgcagaacactgcagga-3';
GPX1 c.593C>T, 5'-gggttctagctgcccttctc-3' and 5'-
caggtgttcctccctcgtag-3'. Direct sequencing of the PCR
products was performed on both forward and reverse
strands using the same primers for PCR and cycle
sequencing using v3.1 BigDye terminator sequencing kit
on an ABI 313Oxl Genetic Analyzer (Applied Biosystems,
Foster City, CA, USA).  
Statistical analysis
Unless otherwise noted, the data are presented as the
means ± standard deviation for continuous variables, and
the frequency, in percent, for the categorical variables.
Statistical analysis was performed with SPSS version 12.0
(SPSS Inc., Chicago, IL, USA), and all p values < 0.05
were considered statistically significant. The differences
between groups were compared with the Student’s t test
for continuous variables, and the χ2 test or Fisher’s exact
test for categorical variables. The results of the logistic
regression analysis are reported as odds ratios with 95%
confidence interval (CI). 
RESULTS
Table 1 summarizes the baseline characteristics of the
patients, including age, gender, amount of PQ ingested,
time lag after PQ ingestion to arrival in the ER, and initial
laboratory findings. Among the 62 cases, 23 patients
(37.1%) died. Table 2 summarizes the antioxidant activity
in stored whole blood samples taken from these patients.
Neither erythrocyte SOD nor catalase activity showed a
difference between the survivors and non-survivors.
Differences in initial laboratory parameters between
Table 2. Parameters of survivors and non-survivors
Parameters Survivor Non-survivor p value
Catalase activity, µmol/min/mL  78.7 ± 21.3 (81.8)  75.3 ± 24.6 (80.3) 0.615
SOD activity, u/mL 65.0 ± 15.9 (64.8) 74.4 ± 18.9 (71.9)  0.099
Amount of PQ ingested, mL 25.7 ± 19.3 (20)  53.5 ± 98.7 (40) 0.025
Time elapsed after PQ ingestion, hr 7.1 ± 5.9 (4)  7.6 ± 5.6 (6) 0.253
PQ level, µg/mL 0.22 ± 0.26 (0.13)  0.83 ± 0.63 (0.55) 0.000
TAS, mmol/L 1.67 ± 0.26 (1.64)  1.77 ± 0.15 (1.80)  0.024
MDA, µM 11.58 ± 3.70 (10.75)  12.50 ± 4.77 (13.15)  0.739
Initial laboratory findings
WBC, × 103/L  10.11 ± 6.39  12.16 ± 5.07  0.035
Hemoglobin, g/dL 13.46 ± 2.08  14.08 ± 1.79  0.318
Hematocrit, % 39.82 ± 5.24  41.30 ± 4.53  0.351
Platelet, × 103/L 213.64 ± 60.98  211.70 ± 52.58  0.550
Albumin, g/dL 4.25 ± 0.43  4.23 ± 0.65  0.753
Bilirubin, mg/dL 0.85 ± 0.78  1.11 ± 1.36  0.739
AST, IU/L 35.03 ± 22.95  40.91 ± 31.82  0.035
ALT, IU/L 25.41 ± 15.33  34.65 ± 57.07  0.318
BUN, mg/dL 11.99 ± 4.21  13.77 ± 5.52  0.351
Creatinine, mg/dL 0.64 ± 0.29  0.80 ± 0.54  0.550
Uric acid, mg/dL 4.76 ± 1.67  4.55 ± 1.69  0.753
Amylase, IU/L 229.62 ± 251.06  169.00 ± 102.82  0.605
Lipase, IU/L 45.74 ± 70.39  36.09 ± 22.12  0.180
pH 7.42 ± 0.06  7.41 ± 0.06  0.560
PaO2, mmHg 88.30 ± 15.66  88.50 ± 16.06  0.035
Values are presented as mean ± SD (median). 
SOD, superoxide dismutase; PQ, paraquat; TAS, total antioxidant status; MDA, malondialdehyde; WBC, white blood cell count; AST, aspartate
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survivors and non-survivors was also not noted, although
the PQ level was higher in the non-survivor group than
survivor group.
The Val allele of Mn-SOD and C allele of the catalase
gene did not differ between survivors and non-survivors
(Table 3). Non-survivors tended to have a higher frequency
of the C/T catalase allele, which was not detected in
survivors. The odds ratio of the Mn-SOD Val allele for
non-survivors was 0.300 (95% CI, 0.075 to 1.197); that of
the catalase C allele for non-survivors was 1.211 (95% CI,
1.004 to 1.460). All four patients with the C/T allele of
catalase died, whereas only 32.78% patients with the T/T
allele of catalase died. This suggests a high death rate in
patients with the C/T allele of catalase, but the sample size
was too small for statistical analysis and there was no
statistical significance in multiple logistic regression
analysis. The GPX1 c. C/C, C/T, and T/T genotypes were
present in 100/0/0% of subjects.
There were no significant differences in SOD enzyme
activity between genetic polymorphisms (78.6 ± 20.6
U/mL for the T/T genotype and 70.5 ± 15.3 U/mL for the
T/C genotype, p = 0.774, Mann-Whitney test) or in
catalase enzyme activity between genetic polymorphisms
(78.6 ± 20.6 µmol/min/mL for the C/C genotype and 70.5
± 15.3 µmol/min/mL for the C/T genotype, p = 0.479,
Mann-Whitney test) (Fig. 2).
DISCUSSION
We have treated many patients with acute PQ intoxi-
cation and have noted that some die at relatively low PQ
concentrations whereas others recover [7,16]. The present
study was designed to determine whether individual
differences in antioxidant capacity might be responsible
for this variable clinical outcome. Contrary to our expecta-
tions, no significant differences were found in the
distribution of the polymorphisms of MnSOD c.47T>C,
Catalase -262C>T, or GPX1 c.593C>T between survivors
and non-survivors. In addition, there was no significant
differences in total SOD and catalase activity, and the
functional polymorphisms of the Mn-SOD and catalase
Table 3. Genotype distribution, allele frequency, and
risk association with two polymorphisms in survivors
and non-survivors
Survivor (%) Non-survivor (%)
Mn-SOD Ala 16 Val
Genotype
V/V 26 (56.5) 20 (86.9)
V/A 20 (43.5) 3 (13.1)






C/C 39 (100) 19 (82.6)
C/T 0 (0) 4 (17.4)
T/T 0 (0) 0 (0)
Allele
C 78 (100) 42
T0 4
Figure 2. Comparison of superoxide dismutase (SOD) and catalase activity according to genotype. (A) There were no significant
differences in SOD activity between the T/T and T/C polymorphism (p = 0.774). (B) There were no significant difference in catalase
activity between the C/C and C/T polymorphism (p = 0.479).  
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genes studied were not associated with changes in
erythrocyte SOD and catalase activity. One explanation for
this may be that Mn-SOD activity accounts for ~90% of
total SOD activity and thus does not specifically measure
total SOD activity. In addition, other polymorphisms
(such as the SOD3 gene +760C>G substitution of arginine
213 with glycine) have been reported to be associated with
differences in individual antioxidant capacity [17]. Thus,
further studies are needed to study the functional
polymorphisms of the two other isoforms of SOD. 
The -262C>T polymorphism in the promoter region of
the human catalase gene is associated with transcription
factor binding and blood catalase levels [12]. Unfortunately,
the homozygous T/T genotype is rare in Asia [18], occurring
in none of the patients in the present population. In this
setting, it is impossible to adequately assess the functional
activity of the T/T genotype. However, there was no
difference in catalase activity between survivors and non-
survivors, regardless of genotype. One previous study
reported significant racial differences in free radical-
scavenging enzyme activity in children [18]. Unfortunately,
the frequency of genetic polymorphisms was extremely
low in both the catalase and GPX genes. Therefore, we
could not perform statistical analysis to understand the
association between these genetic polymorphisms and
clinical outcome in patients with acute PQ intoxication.
One of the strengths of the present study is that the
subjects were recruited from the “gray zone” in which
some patients succumb and others with similar PQ levels
recover. Indeed, plasma PQ concentration is an excellent
prognostic indicator. No patients survived when the PQ
level was in the dead zone and no patient died when the
PQ level was in the safe zone. However, in the gray zone,
some died and others survived. The results of this study
do not explain the reason for the variable outcomes in the
gray zone. There was no association between the genetic
polymorphisms studied and clinical outcome. However,
plasma PQ levels were significantly lower in survivors
than in non-survivors, even in the gray zone. 
Some limitations of this study should be noted. First,
the sample size was small due to the limited number of
patients in the gray zone, and there was no control group.
However, all patients were healthy and similar to the
general population until they attempted suicide. Second,
measurements of antioxidant enzyme activity were based
on erythrocytes only, which might not reflect the local
levels in organs such as the lungs. Third, our study did not
consider many other genetic polymorphisms that have
been proposed as potential factors that could explain
individual differences in antioxidant capacity. Fourth,
individual differences in the capacity to reduce PQ to the
mono-cation radical could potentially cause heterogeneous
clinical outcomes because PQ must first be reduced to
mediate ROS formation. Finally, measurements of SOD
and catalase activity were performed at one random point
in time, which does not reflect the possible variability in
these parameters over time. 
Enzymatic defense against ROS involves the cooperative
action of several antioxidant enzymes. SOD is one of the
key enzymes that reacts with O2•- to generate H2O2,
which acts as a substrate for GPX and catalase to form
H2O [19]. The results of studies on antioxidant enzyme
activity have been controversial with regard to ROS-
implicated diseases. The activities of SOD and catalase
increase after smoking in human alveolar macrophages
[20]. However, other studies on animal models with severe
or chronic oxidant exposure have demonstrated that the
induction of Mn-SOD is transient and that antioxidant
enzymes may even be down-regulated [21]. Our results
suggest that the clinical outcome of acute PQ intoxication
is not influenced by individual differences in antioxidant
capacity. Even if individual variation in antioxidant
capacity does affect the clinical outcome of patients with
so-called ROS-implicated diseases [22-26], PQ
intoxication might overwhelm the system.  
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